FINWIRES · TerminalLIVE
FINWIRES

Insilico Medicine Nominates AI-Developed Brain Cancer Drug Candidate

By

-- Insilico Medicine (HKG:3696) has nominated a new preclinical drug candidate for glioblastoma using its artificial intelligence platform, according to a Friday Hong Kong bourse filing.

The candidate, ISM0387, was developed by the company's United Arab Emirates team using its Pharma.AI system and progressed from design to optimization in under 12 months.

Insilico said the drug showed improved activity, selectivity, and brain penetration in early studies, with potential as a treatment for brain cancer.

Related Articles

International

South Korea's Monthly Industrial Production Growth Decelerates Sharply in March

South Korea's overall industrial output increased 0.3% month-on-month in March, decelerating sharply from a 5.3% monthly rise in February, according to data from Statistics Korea released Thursday.The construction and public administration indices fell by 7.3% and 3.3%, respectively, in March from the prior month, while the index for the service, mining and manufacturing industries added 1.4% and 0.3%, respectively.Total industrial production increased by 3.6% in March from the same month in 2025, after a 2.3% yearly decline in February.

$^KOSDAQ$^KS11
Asia

NZX Midday Sector Update: Consumer Durables Sector Soars, Non-Energy Minerals Decline

Shares of the consumer durables sector gained the most on New Zealand's Exchange, rising past 3% on Thursday.Shares of KMD Brands (NZE:KMD, ASX:KMD) rose over 3% in recent trade.Meanwhile, non-energy minerals shares fell 1%.Fletcher Building (NZE:FBU, ASX:FBU) was down nearly 1% in recent trade.

$^NZ50$ASX:FBU$ASX:KMD$NZE:FBU$NZE:KMD
Asia

Midea's Q1 Profit Rises 2%, Revenue Climbs 3%

Midea's (SHE:000333, HKG:0300) net profit attributable to shareholders in the first quarter rose 2% to 12.7 billion yuan from 12.4 billion yuan a year earlier, according to a Hong Kong filing on Thursday.Earnings per share increased 3.7% year on year to 1.69 yuan from 1.63 yuan. Current EPS beat Visible Alpha's estimate of 1.65 yuan.Operating revenue was 131.1 billion yuan, 2.6% higher than 127.8 billion yuan in the previous year and higher than VA analysts' forecast of 131 billion yuan.

$HKG:0300$SHE:000333